Moreover, both fingolimod and the pharmacological activator K6PC-6 significantly reduced apoptosis in an HD cellular model and increased the activation of Akt and Erk signalling pathways (Di Pardo et al., 2017), whose regulation is known to be defective in HD (Bowles and Jones, 2014). Here, AKT1 is linked to Huntington disease.